Healthcare / BiotechnologyTokyo
$103.00
-6.00 (-5.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-1.8B · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-73.3%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-1.79B · FCF $-1.84B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $2.50B | — |
| Net Income | $-1.79B | $-1.79B | $-1.83B | $223.3M | $-1.78B |
| EBITDA | $-1.79B | $-1.79B | $-1.80B | $218.1M | $-1.83B |
| EPS | -26.03 | -26.03 | -31.11 | 3.96 | -31.52 |
| Gross Margin | — | — | — | 20.1% | — |
| Operating Margin | — | — | — | 8.5% | — |
| Net Margin | — | — | — | 8.9% | — |
| Balance Sheet | |||||
| Current Ratio | 12.68 | 12.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.84B | $-1.84B | $-1.94B | $543.0M | $-1.72B |
| Returns | |||||
| ROE | -73.3% | -73.3% | -43.9% | 5.0% | -41.6% |
| Valuation | |||||
| P/B | 2.90 | 2.90 | 9.46 | — | — |
| Growth & Yield | |||||
| EPS Growth | 16.3% | 16.3% | -885.6% | 112.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-55.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-31.11 → -26.03
Residual
-55.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.